Search Medical Condition
Please enter condition
Please choose location from dropdown

Tempe, Arizona Clinical Trials

A listing of Tempe, Arizona clinical trials actively recruiting patient volunteers.

RESULTS

Found (675) clinical trials

Dabrafenib and/or Trametinib Rollover Study

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued ...

Phase

9.99 miles

Learn More »

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

This study is a Phase 2/3 prospective, double-blind, randomized, multi-center, placebocontrolled study for prevention of acute GVHD (aGVHD) in subjects undergoing an allogeneic hematopoietic cell transplant (HCT).

Phase

9.99 miles

Learn More »

Study of TJ004309 in Combination With Atezolizumab (Tecentriq ) in Patients With Advanced or Metastatic Cancer

This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination with standard dose atezolizumab in patients with advanced or metastatic cancer in patients who are refractory to or intolerant to all available therapy.

Phase

9.99 miles

Learn More »

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to ...

Phase

9.99 miles

Learn More »

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

This Phase 1 study will enroll approximately 36 evaluable adult subjects with refractory, advanced cancer (solid tumors) regardless of diagnosis and prior therapies. Subjects who discontinue early for reason other than DLT will be replaced. The biopharmacological properties of the antibody suggest that this proposed dose range will be safe ...

Phase

9.99 miles

Learn More »

A Dose Escalation Study of PF 06939999 in Participants With Advanced or Metastatic Solid Tumors.

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.

Phase

9.99 miles

Learn More »

A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of RO7198457 plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

Phase

9.99 miles

Learn More »

This study is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary anti-tumor activity of INCMGA00012 administered IV every two or four weeks in patients with relapsed/refractory, unresectable locally advanced or metastatic solid tumors.  The study consists of ...

Phase

9.99 miles

Learn More »

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

This study is an open-label, Phase 1b study evaluating TRK-950 in combination with 1) FOLFIRI or 2) Gemcitabine / Cisplatin or 3) Gemcitabine / Carboplatin or 4) Ramucirumab/Paclitaxel or 5) PD1 inhibitors (Nivolumab or Pembrolizumab) or 6) Imiquimod Cream for subcutaneous lesions in Patients with Selected Advanced Solid Tumors. The ...

Phase

9.99 miles

Learn More »

Disrupt CAD III With the Shockwave Coronary IVL System

Subject Population: Subjects 18 years of age with de novo, calcified coronary artery lesions presenting with stable, unstable or silent ischemia that are suitable for percutaneous coronary intervention (PCI). Approximately 392 subjects at 50 sites will be enrolled. A minimum of 50% of the total enrollment will come from the ...

Phase N/A

9.99 miles

Learn More »